A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein

Clinical trial NCT04147819 · COMPLETED

Trial details

NCT number: NCT04147819
Sponsor: Bayer
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Cancers With HER2 Expression

Start date: 2020-07-02
Primary completion: 2023-08-21
Enrollment: 14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.